{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T12:31:40Z","timestamp":1777984300138,"version":"3.51.4"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:00:00Z","timestamp":1773446400000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"DOI":"10.1186\/s40360-026-01099-y","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T01:54:10Z","timestamp":1770602050000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["To investigate the effect of a high-fat diet on pharmacokinetics\/renal function\/RAAS-related parameters after a single dose of empagliflozin in healthy Chinese adults"],"prefix":"10.1186","volume":"27","author":[{"given":"Yi","family":"Jin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenyan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunqi","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuangshuang","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaodi","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6325-062X","authenticated-orcid":false,"given":"Hui","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"key":"1099_CR1","doi-asserted-by":"publisher","first-page":"101817","DOI":"10.1016\/j.cpcardiol.2023.101817","volume":"48","author":"C Cunningham","year":"2023","unstructured":"Cunningham C, Jabri A, Alhuneafat L, Aneja A. A comprehensive guide to sodium glucose cotransport inhibitors. Curr Probl Cardiol. 2023;48:101817.","journal-title":"Curr Probl Cardiol"},{"key":"1099_CR2","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41581-022-00535-6","volume":"18","author":"AB van der Aart-van der Beek","year":"2022","unstructured":"van der Aart-van der Beek AB, de Boer RA, Heerspink HJL. Kidney and heart failure outcomes associated with SGLT2 inhibitor use. Nat Rev Nephrol. 2022;18:294\u2013306.","journal-title":"Nat Rev Nephrol"},{"key":"1099_CR3","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41574-020-0392-2","volume":"16","author":"AJ Scheen","year":"2020","unstructured":"Scheen AJ. Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2020;16:556\u201377.","journal-title":"Nat Rev Endocrinol"},{"key":"1099_CR4","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1111\/dom.15041","volume":"25","author":"L Ji","year":"2023","unstructured":"Ji L, Lu Y, Li Q, Fu L, Luo Y, Lei T, et al. Efficacy and safety of empagliflozin in combination with insulin in Chinese patients with type 2 diabetes and insufficient glycaemic control: a phase III, randomized, double-blind, placebo-controlled, parallel study. Diabetes Obes Metab. 2023;25:1839\u201348.","journal-title":"Diabetes Obes Metab"},{"key":"1099_CR5","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.kint.2020.10.031","volume":"99","author":"BJ Kraus","year":"2021","unstructured":"Kraus BJ, Weir MR, Bakris GL, Mattheus M, Cherney DZI, Sattar N, et al. Characterization and implications of the initial estimated glomerular filtration rate \u2018dip\u2019 upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the empa-reg outcome trial. Kidney Int. 2021;99:750\u201362.","journal-title":"Kidney Int"},{"key":"1099_CR6","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1007\/s13346-023-01423-7","volume":"14","author":"RW Hammad","year":"2024","unstructured":"Hammad RW, Sanad RA, Abdelmalak NS, Latif R. Cubosomal functionalized block copolymer platform for dual delivery of linagliptin and empagliflozin: recent advances in synergistic strategies for maximizing control of high-risk type ii diabetes. Drug Deliv Transl Res. 2024;14:678\u201395.","journal-title":"Drug Deliv Transl Res"},{"key":"1099_CR7","doi-asserted-by":"publisher","first-page":"3568","DOI":"10.1007\/s13346-024-01658-y","volume":"14","author":"P Wagh","year":"2024","unstructured":"Wagh P, Savaliya S, Joshi B, Vyas B, Kuperkar K, Lalan M, et al. Discerning computational, in vitro and in vivo investigations of self-assembling empagliflozin polymeric micelles in type-2 diabetes. Drug Deliv Transl Res. 2024;14:3568\u201384.","journal-title":"Drug Deliv Transl Res"},{"key":"1099_CR8","doi-asserted-by":"crossref","unstructured":"Cheng L, Wong H. Food effects on oral drug absorption: application of physiologically-based pharmacokinetic modeling as a predictive tool. Pharmaceutics. 2020;12.","DOI":"10.3390\/pharmaceutics12070672"},{"key":"1099_CR9","doi-asserted-by":"crossref","unstructured":"Niederberger E, Parnham MJ. The impact of diet and exercise on drug responses. Int J Mol Sci. 2021;22.","DOI":"10.3390\/ijms22147692"},{"key":"1099_CR10","first-page":"2741","volume":"38","author":"L Xb","year":"2022","unstructured":"Xb L, Wang N, Yu M, Nn H, Wang N, Qi W, et al. Pharmacokinetics and bioequivalence studies of empagliflozin tablets in Chinese healthy subjects. Chin J Clin Pharmacol. 2022;38:2741\u201345.","journal-title":"Chin J Clin Pharmacol"},{"key":"1099_CR11","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1080\/03639045.2020.1810263","volume":"46","author":"X Li","year":"2020","unstructured":"Li X, Liu L, Deng Y, Li Y, Zhang P, Wang Y, et al. Pharmacokinetics and bioequivalence of a generic empagliflozin tablet versus a brand-named product and the food effects in healthy Chinese subjects. Drug Dev Ind Pharm. 2020;46:1487\u201394.","journal-title":"Drug Dev Ind Pharm"},{"key":"1099_CR12","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/cpdd.16","volume":"2","author":"L Seman","year":"2013","unstructured":"Seman L, Macha S, Nehmiz G, Simons G, Ren B, Pinnetti S, et al. Empagliflozin (bi 10773), a potent and selective SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Drug Dev. 2013;2:152\u201361.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"1099_CR13","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1002\/phar.2432","volume":"40","author":"G Chen","year":"2020","unstructured":"Chen G, Zhang D, Du A, Zhang Y, Zhang Y, Zhang L, et al. Pharmacokinetics, safety, and bioequivalence of two empagliflozin formulations after single oral administration under fasting and fed conditions in healthy Chinese subjects: an open-label randomized single-dose two-sequence, two-treatment, two-period crossover study. Pharmacotherapy. 2020;40:623\u201331.","journal-title":"Pharmacotherapy"},{"key":"1099_CR14","doi-asserted-by":"publisher","first-page":"873","DOI":"10.5414\/CP201948","volume":"51","author":"S Macha","year":"2013","unstructured":"Macha S, Jungnik A, Hohl K, Hobson D, Salsali A, Woerle HJ. Effect of food on the pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, and assessment of dose proportionality in healthy volunteers. Int J Clin Pharmacol Ther. 2013;51:873\u201379.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"1099_CR15","doi-asserted-by":"crossref","unstructured":"Hailat M, Zakaraya Z, Al-Ani I, Meanazel OA, Al-Shdefat R, Anwer MK, et al. Pharmacokinetics and bioequivalence of two empagliflozin, with evaluation in healthy Jordanian subjects under fasting and fed conditions. Pharmaceuticals (Basel). 2022;15.","DOI":"10.3390\/ph15020193"},{"key":"1099_CR16","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.2147\/DDDT.S470826","volume":"18","author":"XD Yang","year":"2024","unstructured":"Yang XD, Yang YY. Clinical pharmacokinetics of semaglutide: a systematic review. Drug Des Devel Ther. 2024;18:2555\u201370.","journal-title":"Drug Des Devel Ther"},{"key":"1099_CR17","doi-asserted-by":"crossref","unstructured":"Podest\u00e0 MA, Sabiu G, Galassi A, Ciceri P, Cozzolino M. SGLT2 inhibitors in diabetic and non-diabetic chronic kidney disease. Biomedicines. 2023;11.","DOI":"10.3390\/biomedicines11020279"},{"key":"1099_CR18","doi-asserted-by":"crossref","unstructured":"Group E-KC. Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the empa-kidney trial. Lancet Diabetes Endocrinol. 2024;12:51\u201360.","DOI":"10.1016\/S2213-8587(23)00322-4"},{"key":"1099_CR19","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1056\/NEJMoa2409183","volume":"392","author":"WG Herrington","year":"2025","unstructured":"Herrington WG, Staplin N, Agrawal N, Wanner C, Green JB, Hauske SJ, et al. Long-term effects of empagliflozin in patients with chronic kidney disease. N Engl J Med. 2025;392:777\u201387.","journal-title":"N Engl J Med"},{"key":"1099_CR20","doi-asserted-by":"crossref","unstructured":"Malijan GB, Sardell RJ, Staplin N, Devuyst O, Chapman D, Hill M, et al. Effects of empagliflozin on urine biomarkers in empa-kidney. Am J Kidney Dis. 2025.","DOI":"10.1053\/j.ajkd.2025.10.004"},{"key":"1099_CR21","doi-asserted-by":"publisher","first-page":"113357","DOI":"10.1016\/j.biopha.2022.113357","volume":"153","author":"C Chu","year":"2022","unstructured":"Chu C, Deli\u0107 D, Alber J, Feger M, Xiong Y, Luo T, et al. Head-to-head comparison of two sglt-2 inhibitors on aki outcomes in a rat ischemia-reperfusion model. Biomed Pharmacother. 2022;153:113357.","journal-title":"Biomed Pharmacother"},{"key":"1099_CR22","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.59556\/japi.72.0759","volume":"72","author":"AR Asirvatham","year":"2024","unstructured":"Asirvatham AR, Asirvatham AJ, Mahadevan S. SGLT2 inhibitors and finerenone: a friendly duo in the treatment of diabetic kidney disease? J Assoc Physicians India. 2024;72:e35\u201341.","journal-title":"J Assoc Physicians India"},{"key":"1099_CR23","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S0140-6736(23)02408-X","volume":"403","author":"KR Tuttle","year":"2024","unstructured":"Tuttle KR, Hauske SJ, Canziani ME, Caramori ML, Cherney D, Cronin L, et al. Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial. Lancet. 2024;403:379\u201390.","journal-title":"Lancet"},{"key":"1099_CR24","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s40262-013-0126-x","volume":"53","author":"AJ Scheen","year":"2014","unstructured":"Scheen AJ. Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor. Clin Pharmacokinet. 2014;53:213\u201325.","journal-title":"Clin Pharmacokinet"},{"key":"1099_CR25","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1161\/CIRCULATIONAHA.120.045691","volume":"142","author":"M Griffin","year":"2020","unstructured":"Griffin M, Rao VS, Ivey-Miranda J, Fleming J, Mahoney D, Maulion C, et al. Empagliflozin in heart failure: diuretic and cardiorenal effects. Circulation. 2020;142:1028\u201339.","journal-title":"Circulation"},{"key":"1099_CR26","doi-asserted-by":"publisher","first-page":"2758","DOI":"10.18549\/PharmPract.2023.1.2758","volume":"21","author":"JS Al-Maqbali","year":"2023","unstructured":"Al-Maqbali JS, Alawi AMA, Al-Adawi M, Al-Falahi Z, Al-Azizi A, Al Badi K, et al. Clinical associations with the differences in rivaroxaban dosing in patients with atrial fibrillation stratified by three renal function formulae. Pharm Pract (Granada). 2023;21:2758.","journal-title":"Pharm Pract (Granada)"},{"key":"1099_CR27","unstructured":"NMPA. Technical guidelines for food impact studies in new drug development. National Medical Products Administration. 2021. https:\/\/www.cde.org.cn\/main\/news\/viewInfoCommon\/4f21fc720672cf26ad0efbe0207fdced."},{"key":"1099_CR28","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1002\/cpdd.1163","volume":"11","author":"JH Hughes","year":"2022","unstructured":"Hughes JH, Qiu R, Banfield C, Dowty ME, Nicholas T. Population pharmacokinetics of oral brepocitinib in healthy volunteers and patients. Clin Pharmacol Drug Dev. 2022;11:1447\u201356.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"1099_CR29","doi-asserted-by":"publisher","first-page":"e01102","DOI":"10.1002\/prp2.1102","volume":"11","author":"Q Wu","year":"2023","unstructured":"Wu Q, Zhu H, Song R, Zhang M, Li F, Zeng W, et al. Effect of a high-fat and high-calorie food on the pharmacokinetics of a novel, potent gaba analog hsk16149 in healthy subjects. Pharmacol Res Perspect. 2023;11:e01102.","journal-title":"Pharmacol Res Perspect"},{"key":"1099_CR30","unstructured":"FDA. Food-effect bioavailability and fed bioequivalence studies. U.S. Food and Drug Administration. 2002. https:\/\/www.fda.gov\/regulatory-Information\/search-Fda-Guidance-Documents\/food-Effect-Bioavailability-And-Fed-Bioequivalence-Studies."},{"key":"1099_CR31","doi-asserted-by":"publisher","first-page":"105812","DOI":"10.1016\/j.ejps.2021.105812","volume":"162","author":"Z Vinarov","year":"2021","unstructured":"Vinarov Z, Abdallah M, Agundez JAG, Allegaert K, Basit AW, Braeckmans M, et al. Impact of gastrointestinal tract variability on oral drug absorption and pharmacokinetics: an ungap review. Eur J Pharm Sci. 2021;162:105812.","journal-title":"Eur J Pharm Sci"},{"key":"1099_CR32","doi-asserted-by":"publisher","first-page":"101032","DOI":"10.1016\/j.dmpk.2024.101032","volume":"59","author":"A Watanabe","year":"2024","unstructured":"Watanabe A, Akazawa T, Fujiu M. Understanding mechanisms of negative food effect for voclosporin using physiologically based pharmacokinetic modeling. Drug Metab Pharmacokinet. 2024;59:101032.","journal-title":"Drug Metab Pharmacokinet"},{"key":"1099_CR33","first-page":"1843","volume":"32","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Gao H, Cui X, Ren J, Wang W, Zheng X. Advances in studies of the food effects on oral drugs. Chin J New Drugs. 2023;32:1843\u201349.","journal-title":"Chin J New Drugs"},{"key":"1099_CR34","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1111\/cts.13566","volume":"16","author":"D Kim","year":"2023","unstructured":"Kim D, Choi M, Jin BH, Hong T, Kim CO, Yoo BW, et al. Pharmacokinetic and pharmacodynamic drug-drug interactions between evogliptin and empagliflozin or dapagliflozin in healthy male volunteers. Clin Transl Sci. 2023;16:1469\u201378.","journal-title":"Clin Transl Sci"},{"key":"1099_CR35","doi-asserted-by":"publisher","first-page":"59","DOI":"10.12793\/tcp.2023.31.e4","volume":"31","author":"H Kim","year":"2023","unstructured":"Kim H, Kim CO, Park H, Park MS, Kim D, Hong T, et al. Evaluation of pharmacokinetic interactions between lobeglitazone, empagliflozin, and metformin in healthy subjects. Transl Clin Pharmacol. 2023;31:59\u201368.","journal-title":"Transl Clin Pharmacol"},{"key":"1099_CR36","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/1440-1681.13611","volume":"49","author":"R Shao","year":"2022","unstructured":"Shao R, Chen W, Ruan Z, Yang D, Chen W, Li H, et al. Effects of food on the pharmacokinetics of ensartinib in healthy Chinese subjects. Clin Exp Pharmacol Physiol. 2022;49:360\u201369.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"1099_CR37","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13098-024-01547-x","volume":"17","author":"MJ Cao","year":"2025","unstructured":"Cao MJ, Liang TT, Xu L, Shi FH. Evaluating the overall renal outcomes of sodium-glucose cotransporter-2 (SGLT2) inhibitors in patients with chronic kidney disease (CKD). Diabetol Metab Syndr. 2025;17:5.","journal-title":"Diabetol Metab Syndr"},{"key":"1099_CR38","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1021\/acs.chemrestox.5c00099","volume":"38","author":"R Kalahasthi","year":"2025","unstructured":"Kalahasthi R, Nagaraju R, Balachandar R, Upadhyay K, Bagepally BS. Association between occupational cadmium exposure and markers of kidney injury: a systematic review and meta-analysis. Chem Res Toxicol. 2025;38:1638\u201351.","journal-title":"Chem Res Toxicol"},{"key":"1099_CR39","doi-asserted-by":"publisher","first-page":"1173982","DOI":"10.3389\/fphys.2023.1173982","volume":"14","author":"Y Zhou","year":"2023","unstructured":"Zhou Y, Zhang Y, Chen J, Wang T, Li H, Wu F, et al. Diagnostic value of \u03b11-mg and urbp in early diabetic renal impairment. Front Physiol. 2023;14:1173982.","journal-title":"Front Physiol"},{"key":"1099_CR40","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1161\/CIRCULATIONAHA.122.059038","volume":"146","author":"PC Schulze","year":"2022","unstructured":"Schulze PC, Bogoviku J, Westphal J, Aftanski P, Haertel F, Grund S, et al. Effects of early empagliflozin initiation on diuresis and kidney function in patients with acute decompensated heart failure (empag-hf). Circulation. 2022;146:289\u201398.","journal-title":"Circulation"},{"key":"1099_CR41","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1002\/jimd.12752","volume":"47","author":"RJ Overduin","year":"2024","unstructured":"Overduin RJ, Gr\u00fcnert SC, Besouw MTP, Bolhuis MS, Groen J, Schreuder AB, et al. Repurposing SGLT2 inhibitors: treatment of renal proximal tubulopathy in fanconi-bickel syndrome with empagliflozin. J Inherit Metab Dis. 2024;47:1018\u201327.","journal-title":"J Inherit Metab Dis"},{"key":"1099_CR42","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.2337\/dc20-0456","volume":"43","author":"E Ferrannini","year":"2020","unstructured":"Ferrannini E, Murthy AC, Lee YH, Muscelli E, Weiss S, Ostroff RM, et al. Mechanisms of sodium-glucose cotransporter 2 inhibition: insights from large-scale proteomics. Diabetes Care. 2020;43:2183\u201389.","journal-title":"Diabetes Care"},{"key":"1099_CR43","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s12325-021-02006-z","volume":"39","author":"JJ Garcia Sanchez","year":"2022","unstructured":"Garcia Sanchez JJ, Thompson J, Scott DA, Evans R, Rao N, S\u00f6rstadius E, et al. Treatments for chronic kidney disease: a systematic literature review of randomized controlled trials. Adv Ther. 2022;39:193\u2013220.","journal-title":"Adv Ther"},{"key":"1099_CR44","doi-asserted-by":"publisher","first-page":"e016173","DOI":"10.1161\/JAHA.119.016173","volume":"9","author":"A Zanchi","year":"2020","unstructured":"Zanchi A, Burnier M, Muller ME, Ghajarzadeh-Wurzner A, Maillard M, Loncle N, et al. Acute and chronic effects of SGLT2 inhibitor empagliflozin on renal oxygenation and blood pressure control in nondiabetic normotensive subjects: a randomized, placebo-controlled trial. J Am Heart Assoc. 2020;9:e016173.","journal-title":"J Am Heart Assoc"},{"key":"1099_CR45","doi-asserted-by":"publisher","first-page":"15449","DOI":"10.1038\/s41598-024-66454-7","volume":"14","author":"Z Zhou","year":"2024","unstructured":"Zhou Z, Xu M, Bian M, Nie A, Sun B, Zhu C. Anti-hyperuricemia effect of clerodendranthus spicatus: a molecular biology study combined with metabolomics. Sci Rep. 2024;14:15449.","journal-title":"Sci Rep"},{"key":"1099_CR46","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1111\/dme.13956","volume":"36","author":"J Chen","year":"2019","unstructured":"Chen J, Qiu SH, Guo HJ, Li W, Sun ZL. Increased urinary glucose excretion is associated with a reduced risk of hyperuricaemia. Diabet Med. 2019;36:902\u201307.","journal-title":"Diabet Med"},{"key":"1099_CR47","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1111\/dom.15404","volume":"26","author":"S Abdelgani","year":"2024","unstructured":"Abdelgani S, Khattab A, Adams J, Baskoy G, Triplitt C, DeFronzo RA, et al. The impact of increased hepatic glucose production caused by empagliflozin on plasma glucose concentration in individuals with type 2 diabetes and nondiabetic individuals. Diabetes Obes Metab. 2024;26:1033\u201339.","journal-title":"Diabetes Obes Metab"},{"key":"1099_CR48","doi-asserted-by":"publisher","first-page":"e230124226010","DOI":"10.2174\/0115733998271026231127051545","volume":"20","author":"J Yadav","year":"2024","unstructured":"Yadav J, Ahsan F, Panda P, Mahmood T, Ansari VA, Shamim A. Empagliflozin-a sodium glucose co-transporter-2 inhibitor: overview ofits chemistry, pharmacology, and toxicology. Curr Diabetes Rev. 2024;20:e230124226010.","journal-title":"Curr Diabetes Rev"},{"key":"1099_CR49","doi-asserted-by":"publisher","first-page":"796521","DOI":"10.3389\/fendo.2022.796521","volume":"13","author":"MF Villa-Tamayo","year":"2022","unstructured":"Villa-Tamayo MF, Garc\u00eda-Jaramillo M, Le\u00f3n-Vargas F, Rivadeneira PS. Interval safety layer coupled with an impulsive mpc for artificial pancreas to handle intrapatient variability. Front Endocrinol (Lausanne). 2022;13:796521.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1099_CR50","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.1007\/s12325-024-02879-w","volume":"41","author":"C Wanner","year":"2024","unstructured":"Wanner C, Iliev H, Duarte N, Schueler E, Soares AR, Thanam V, et al. Safety of empagliflozin: an individual participant-level data meta-analysis from four large trials. Adv Ther. 2024;41:2826\u201344.","journal-title":"Adv Ther"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-026-01099-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-026-01099-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-026-01099-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T12:02:26Z","timestamp":1773489746000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40360-026-01099-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1099"],"URL":"https:\/\/doi.org\/10.1186\/s40360-026-01099-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7748740\/v1","asserted-by":"object"}]},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,9]]},"assertion":[{"value":"30 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Ethics Committee of Shanxi Provincial People\u2019s Hospital (BE protocol code: 2023-045, approval date: 27-7-2023, PD protocol code: 2023\u2013364 (fasting) and 2023\u2013399 (fed), approval date:29-8-2023 (fasting) and 28-9-2023 (fed)).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained from all participants involved in the study. Written informed consent has been obtained from the participants to publish this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"47"}}